CAJ | 학술논문

新诊断2型糖尿病的治疗策略存在争议。糖化血红蛋白（HbA1c）≥9％曾被认为是胰岛素强化治疗的切点，但胰岛素降糖治疗低血糖风险增加，体重增加明显，心血管疾病风险不减疑惑难消，而口服降糖药与胰岛素在治疗新诊断2型糖尿病时，缓解率相似，患者依从性高。在糖尿病的初始治疗中，应当按照我国糖尿病防治指南的推荐，积极合理用药，并及时优化药物的剂量，充分首选口服降糖药。只有2种～3种口服降糖药联合治疗不达标时，才是启用胰岛素的最佳时机。
신진단2형당뇨병적치료책략존재쟁의。당화혈홍단백（HbA1c）≥9％증피인위시이도소강화치료적절점，단이도소강당치료저혈당풍험증가，체중증가명현，심혈관질병풍험불감의혹난소，이구복강당약여이도소재치료신진단2형당뇨병시，완해솔상사，환자의종성고。재당뇨병적초시치료중，응당안조아국당뇨병방치지남적추천，적겁합리용약，병급시우화약물적제량，충분수선구복강당약。지유2충～3충구복강당약연합치료불체표시，재시계용이도소적최가시궤。
Newly diagnosed type 2 diabetes mellitus treatment strategies remain controversy . Glycosylated hemoglobin (HbA1c) more than 9% was considered as a tangent point of initiation of insulin intensive therapy .However ,insulin intensive therapy increased the risk of hypoglycemia ,gaining weight ,and the risk of cardiovascular disease decreased or not remained uncertain .In addition ,the remission rate was similar among the newly diagnosed type 2 diabetes mellitus patients with oral medications treatment and those of insulin therapy .And the patients with oral medication had a higher compliance compared with those of insulin therapy .In the initial treatment of diabetes ,we always prefer oral hypoglycemic medications ,and the prescription should be reasonable and the dosage should be optimized timely in accordance with the our country's recommendation .